KRYSTAL-1 — Adagrasib in KRAS G12C-Mutated Advanced Solid Tumors including NSCLC

Phase 1/2 · 2022 · Non-Small Cell Lung Cancer

Design

Single-arm phase 1/2 evaluation of adagrasib monotherapy.

Population

Previously treated advanced KRAS G12C-mutated NSCLC (and other solid tumors).

Primary Endpoint

objective response rate (ORR)

Key Result

Adagrasib produced an ORR of ~43% with a median duration of response of 8.5 months, including activity in CNS metastases.

Guideline Impact

Second-line KRAS G12C-mutated advanced NSCLC